制癌剤の肝動脈内one shotによる肝細胞癌の治療

概要

論文の詳細を見る
Among 180 patients with unresectable hepatocellular carcinoma, 100 patients were treated with one shot injection of anticancer agents through the hepatic artery. The rest of them had palliative care. Studies were made on the therapeutic effects, indicative selection of patients and untoward effects of the chemotherapy by means of clinical, biochemical, angiographic data and histological examinations. The results were as follows. 1) 33 cases (33%) survived longer than 6 months after the start of chemotherapy (one shot chemotherapy), and 13 cases (13%) of them lived longer than one year. The longest survival was 35 months. 2) Alleviation of upper abdominal pain, regression of liver size and decrease of serum AFP level after the chemotherapy were observed in 45.7%, 31.9% and 46.6%, respectively. 3) Autopsy specimens revealed replacement of fibrous tissue in the tumor area suggesting the chemotherapeutic effect. 4) Patients with intractable ascites and/or overt jaundice were contraindicated for the chemotherapy, and those with sGOT>250u., LDH>600u. and BSP retension (at 45min.) >30% might be not considered for indication of the chemotherapy. 5) Patients with tumors occupying more than 75% of the liver and those with portal trunk opacification in arterial phase of celiac angiograms, had no indication for the chemotherapy. 6) Myelosuppression was observed as a untoward effect of repeated chemotherapy.
社団法人日本肝臓学会の論文